Pinealon
Aliases: Glu-Asp-Arg · EDR
Last verified: 2026-09-23
The short version
A brain-series tripeptide — cognitive support, neuronal hypoxia protection; popular in anti-aging protocols. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical cognition studies. Status: research chemical. Not approved in the West.
Identity & type
- Molecular type
- bioregulator
- Origin
- A brain-series tripeptide — cognitive support, neuronal hypoxia protection; popular in anti-aging protocols.
Mechanism of action
Neuronal gene-expression modulation; antioxidant; serotonergic links.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for Pinealon. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
1–5 mg/day SC in courses. A cognitive bioregulator: users describe calmer clarity and better sleep; often part of the Khavinson protocol.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
A cognitive bioregulator: users describe calmer clarity and better sleep; often part of the Khavinson protocol.
Protocol — official vs community
Official / label
No approved protocol outside domestic Russian/CIS supplement regulation. Research pattern: short courses.
- 015–10 mg SC daily, 10–20 day courses in the research tradition
Duration: Course-based.
Marketed for cognitive/neuroprotective claims with the standard bioregulator evidence profile.
Community (anecdotal)
5–10 mg SC daily for 10–20 days, or oral equivalents of unknown uptake.
- Cycle:
- 1–2× per year, stacked with epitalon in the classic 'bioregulator anti-aging' pairing.
- Break:
- Months between courses.
The epitalon+pinealon pairing is the community's flagship bioregulator combination — the user asking for it by name is the entire evidence story.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical cognition studies.
Preclinical evidence
Preclinical cognition studies.
Known risks
- None reported.characterized
- Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.